

ÅorvarÅ°ur JÅ³n LÃ¶ve

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3679107/publications.pdf>

Version: 2024-02-01

46
papers

3,213
citations

331670

21
h-index

254184

43
g-index

48
all docs

48
docs citations

48
times ranked

3921
citing authors

#	ARTICLE	IF	CITATIONS
1	Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis. Arthritis and Rheumatology, 2016, 68, 1060-1071.	5.6	726
2	Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study. Annals of the Rheumatic Diseases, 2015, 74, 326-332.	0.9	373
3	Obesity and the risk of psoriatic arthritis: a population-based study. Annals of the Rheumatic Diseases, 2012, 71, 1273-1277.	0.9	239
4	Prevalence of the Metabolic Syndrome in Psoriasis. Archives of Dermatology, 2011, 147, 419.	1.4	236
5	Risk of diabetes among patients with rheumatoid arthritis, psoriatic arthritis and psoriasis. Annals of the Rheumatic Diseases, 2010, 69, 2114-2117.	0.9	184
6	Risk for Cardiovascular Disease Early and Late After a Diagnosis of Giant-Cell Arteritis. Annals of Internal Medicine, 2014, 160, 73-80.	3.9	133
7	Diabetes incidence in psoriatic arthritis, psoriasis and rheumatoid arthritis: a UK population-based cohort study. Rheumatology, 2014, 53, 346-352.	1.9	129
8	Peripheral blood T cell responses to keratin peptides that share sequences with streptococcal M proteins are largely restricted to skin-homing CD8+ T cells. Clinical and Experimental Immunology, 2004, 138, 83-93.	2.6	126
9	Risk of venous thromboembolism in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a general population-based cohort study. European Heart Journal, 2018, 39, 3608-3614.	2.2	115
10	The influence of obesity on response to tumour necrosis factor-Î± inhibitors in psoriatic arthritis: results from the DANBIO and ICEBIO registries. Rheumatology, 2016, 55, 2191-2199.	1.9	101
11	Risk of mortality in patients with psoriatic arthritis, rheumatoid arthritis and psoriasis: a longitudinal cohort study. Annals of the Rheumatic Diseases, 2014, 73, 149-153.	0.9	96
12	A strong heritability of psoriatic arthritis over four generations--the Reykjavik Psoriatic Arthritis Study. Rheumatology, 2009, 48, 1424-1428.	1.9	83
13	Physical trauma recorded in primary care is associated with the onset of psoriatic arthritis among patients with psoriasis. Annals of the Rheumatic Diseases, 2017, 76, 521-525.	0.9	77
14	The risk of fracture among patients with psoriatic arthritis and psoriasis: a population-based study. Annals of the Rheumatic Diseases, 2017, 76, 882-885.	0.9	62
15	Cause-specific mortality in patients with psoriatic arthritis and rheumatoid arthritis. Rheumatology, 2017, 56, 907-911.	1.9	59
16	Psoriatic arthritis in Reykjavik, Iceland: prevalence, demographics, and disease course. Journal of Rheumatology, 2007, 34, 2082-8.	2.0	57
17	Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up strategies. Blood Cancer Journal, 2021, 11, 94.	6.2	52
18	Validity of psoriatic arthritis and capture of disease modifying antirheumatic drugs in the health improvement network. Pharmacoepidemiology and Drug Safety, 2014, 23, 918-922.	1.9	48

#	ARTICLE	IF	CITATIONS
19	Small joint involvement in psoriatic arthritis is associated with onycholysis: the Reykjavik Psoriatic Arthritis Study. Scandinavian Journal of Rheumatology, 2010, 39, 299-302.	1.1	40
20	Psoriatic Arthritis and Onycholysis – Results from the Cross-sectional Reykjavik Psoriatic Arthritis Study. Journal of Rheumatology, 2012, 39, 1441-1444.	2.0	34
21	Does biologic therapy impact the development of PsA among patients with psoriasis?. Annals of the Rheumatic Diseases, 2022, 81, 80-86.	0.9	29
22	Effectiveness and treatment retention of TNF inhibitors when used as monotherapy versus comedication with csDMARDs in 15 332 patients with psoriatic arthritis. Data from the EuroSpA collaboration. Annals of the Rheumatic Diseases, 2021, 80, 1410-1418.	0.9	28
23	Validation of Psoriatic Arthritis Diagnoses in Electronic Medical Records Using Natural Language Processing. Seminars in Arthritis and Rheumatism, 2011, 40, 413-420.	3.4	24
24	Body surface area affected by psoriasis and the risk for psoriatic arthritis: a prospective population-based cohort study. Rheumatology, 2022, 61, 1877-1884.	1.9	20
25	Risk Factors for Diagnosis of Psoriatic Arthritis, Psoriasis, Rheumatoid Arthritis, and Ankylosing Spondylitis: A Set of Parallel Case-control Studies. Journal of Rheumatology, 2022, 49, 53-59.	2.0	19
26	Retention and response rates in 14 261 PsA patients starting TNF inhibitor treatment – results from 12 countries in EuroSpA. Rheumatology, 2020, 59, 1640-1650.	1.9	18
27	Comparison of treatment retention and response to secukinumab versus tumour necrosis factor inhibitors in psoriatic arthritis. Rheumatology, 2021, 60, 3635-3645.	1.9	14
28	Infections and the risk of psoriatic arthritis among psoriasis patients: a systematic review. Rheumatology International, 2018, 38, 1385-1397.	3.0	11
29	Screening for Monoclonal Gammopathy of Undetermined Significance: A Population-Based Randomized Clinical Trial. First Results from the Iceland Screens, Treats, or Prevents Multiple Myeloma (iStopMM) Study. Blood, 2021, 138, 156-156.	1.4	10
30	Prevalence, admission rates and hypoxia due to COVID-19 in patients with rheumatic disorders treated with targeted synthetic or biologic disease modifying antirheumatic drugs or methotrexate: a nationwide study from Iceland. Annals of the Rheumatic Diseases, 2021, 80, 671-672.	0.9	9
31	Autoimmunity, Infections, and the Risk of Monoclonal Gammopathy of Undetermined Significance. Frontiers in Immunology, 2022, 13, 876271.	4.8	9
32	Risk of solid cancers overall and by subtypes in patients with psoriatic arthritis treated with TNF inhibitors – a Nordic cohort study. Rheumatology, 2021, 60, 3656-3668.	1.9	8
33	Prevalence of Smoldering Multiple Myeloma: Results from the Iceland Screens, Treats, or Prevents Multiple Myeloma (iStopMM) Study. Blood, 2021, 138, 151-151.	1.4	8
34	Impact of discordance between patient’s and evaluator’s global assessment on treatment outcomes in 14 868 patients with spondyloarthritis. Rheumatology, 2020, 59, 2455-2461.	1.9	7
35	Autoimmune disease is associated with a lower risk of progression in monoclonal gammopathy of undetermined significance. European Journal of Haematology, 2021, 106, 380-388.	2.2	6
36	Golimumab in the treatment of psoriatic arthritis. Expert Review of Clinical Immunology, 2018, 14, 893-898.	3.0	5

#	ARTICLE	IF	CITATIONS
37	Validity of chronic disease diagnoses in Icelandic healthcare registries. Scandinavian Journal of Public Health, 2021, , 140349482110599.	2.3	4
38	OUP accepted manuscript. Rheumatology, 2022, , .	1.9	4
39	Patients with psoriatic arthritis who are not eligible for randomised controlled trials for TNF inhibitors have treatment response and drug survival similar to those who are eligible. RMD Open, 2019, 5, e000984.	3.8	2
40	Defining New Reference Intervals for Serum Free Light Chains in Individuals with Reduced Kidney Function: Results of the Population- Based on Iceland Screens Treats or Prevents Multiple Myeloma (iStopMM) Study. Blood, 2021, 138, 542-542.	1.4	2
41	Monitoring of Circulating Tumor Plasma Cells in Patients with Precursor Conditions of Multiple Myeloma: Data from the Prospective Iceland Screens, Treats, or Prevents Multiple Myeloma (iStopMM) Study. Blood, 2021, 138, 2645-2645.	1.4	2
42	OP0005â€¦INCIDENCE OF OVERALL AND SITE-SPECIFIC CANCERS IN TNF INHIBITOR TREATED PATIENTS WITH PSORIATIC ARTHRITIS: A POPULATION-BASED COHORT STUDY FROM 4 NORDIC COUNTRIES. , 2019, , .		1
43	The first wave of COVIDâ€™19 and concurrent social restrictions were not associated with a negative impact on mental health and psychiatric wellâ€™being. Journal of Internal Medicine, 2022, 291, 837-848.	6.0	1
44	AB0301â€™ANTIMICROBIAL USE IS HIGH IN PATIENTS WITH INFLAMMATORY ARTHRITIDES, AND FURTHER INCREASES WITH FIRST-LINE TNFI THERAPY â€™ NATIONWIDE RESULTS. , 2019, , .		0
45	Monoclonal Gammopathy of Undetermined Significance and COVID-19: Results from the Population-Based Iceland Screens Treats or Prevents Multiple Myeloma Study (iStopMM). Blood, 2021, 138, 154-154.	1.4	0
46	Estimating Selection Bias in Previous Monoclonal Gammopathy of Undetermined Significance Research - the Importance of Screening: Results from the Population-Based Screening Study Iceland Screens, Treats or Prevents Multiple Myeloma (iStopMM). Blood, 2021, 138, 1618-1618.	1.4	0